Tenax Therapeutics (NASDAQ:TENX) stock is soaring higher on Tuesday after the company announced the completion of an oversubscribed private placement for its shares. This oversubscribed private placement has Tenax Therapeutics expecting $100 million in gross proceeds. The company will use this money to continue its Phase 3 LEVEL trial, to start a second Phase 3 trial and for other general purposes. The private placement was led by new investor BVF Partners LP alongside several other investors. It includes 1 ...